

Expression and function of osteopontin variants in HCV-related liver disease and hepatocellular carcinoma

Renée Jade Phillips, B. Biotech (Hons)

THE DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY
THE SCHOOL OF MOLECULAR AND BIOMEDICAL SCIENCE
THE UNIVERSITY OF ADELAIDE



A dissertation submitted to The University of Adelaide

In candidature for the degree of

Doctor of Philosophy in the Faculty of Science

April 2010

Table of Contents

Table of Contents	ii
Abstract.....	xi
Declaration.....	xiii
Presentations and publications related to this thesis	xiv
Acknowledgements	xvi
List of Figures and Tables	xvii
Abbreviations.....	xxii
Materials Providers	xxix
CHAPTER 1: Introduction	1
1.1 Hepatitis C Virus (HCV).....	1
1.1.1 Natural history and classification.....	1
1.1.2 Epidemiology of HCV infection worldwide and in Australia	2
1.1.3 Routes of transmission	2
1.1.4 Types and outcomes of HCV infection.....	3
1.1.4.1 Acute and chronic infection.....	3
1.1.4.2 Progression of CHC-related liver disease	5
1.1.4.3 Pathogenesis of CHC-related liver disease.....	6
1.1.5 Treatment of infection	9
1.1.6 Viral genome and proteins.....	9
1.1.7 Viral replication	11

1.2	Hepatocellular Carcinoma (HCC)	13
1.2.1	Introduction.....	13
1.2.2	Epidemiology.....	13
1.2.3	Underlying causes of HCC tumor development	14
1.2.3.1	Virally-induced HCC	14
1.2.3.1.1	Hepatitis B Virus	14
1.2.3.1.2	Hepatitis C Virus	15
1.2.3.2	Non-viral causes of HCC	18
1.2.4	Treatment options and survival rates	19
1.2.5	Diagnosis	20
1.2.5.1	Current diagnostic techniques.....	20
1.2.5.2	Diagnostic biomarkers of HCC.....	21
1.3	Osteopontin (OPN)	22
1.3.1	Introduction.....	22
1.3.2	Molecular structure	23
1.3.3	Expression, distribution and regulation of OPN	24
1.3.4	OPN receptors.....	26
1.3.4.1	CD44	26
1.3.4.2	Integrins.....	27
1.3.5	Alternatively spliced variants of OPN	28
1.3.6	Functions of OPN and its role in tumorigenesis	29

1.3.7	Downstream signaling pathways regulated by OPN.....	31
1.3.8	Osteopontin as a biomarker of disease and predictor of poor prognostic outcome in cancer.....	33
1.3.9	OPN and HCV-related liver disease	34
1.3.9.1	OPN expression and function during liver injury.....	34
1.3.9.2	OPN expression in patients with chronic HBV and HCV infections	36
1.3.9.3	OPN expression in HCC and its potential use as a diagnostic and prognostic biomarker	37
1.4	Prelude to this study.....	39
1.5	Aims of this project.....	40
CHAPTER 2: Materials and Methods.....		41
2.1	General Reagents.....	41
2.1.1	Plasmid vectors.....	41
2.1.2	Synthetic oligonucleotides.....	42
2.2	Tissue Culture Techniques	42
2.2.1	Tissue culture medium	42
2.2.2	Maintenance of cell lines.....	42
2.2.3	Transient transfection of plasmid DNA	43
2.2.4	Stable transfection of plasmid DNA to generate over-expressing cell lines	43
2.2.5	Transient transfection of Stealth TM siRNA oligonucleotides	44
2.2.6	Preparation of conditioned media	44

2.2.7	Cellular proliferation	45
2.2.8	Trypan blue exclusion	45
2.2.9	Cultured cell lines used in this study.....	45
2.3	Molecular Biology Techniques	47
2.3.1	Transformation of competent bacteria	47
2.3.2	Mini-preparation (small scale) of plasmid DNA	48
2.3.3	Maxi-preparation (large scale) of plasmid DNA	48
2.3.4	Extraction of total RNA and cDNA synthesis	49
2.3.5	RNA quantitation	50
2.3.6	Primer design	51
2.3.7	Polymerase Chain Reaction (PCR)	51
2.3.8	Agarose gel electrophoresis.....	52
2.3.9	Real-time quantitative PCR.....	52
2.3.10	GeneScan [®] genotyping PCR.....	53
2.3.11	Gel purification	53
2.3.12	DNA sequencing.....	54
2.3.13	Restriction endonuclease digestion.....	54
2.3.14	DNA ligation	55
2.3.15	Immunofluorescence staining and microscopy.....	55
2.3.16	Extraction of cellular protein	56
2.3.17	Protein quantification	56

2.3.18	SDS-PAGE and protein transfer	56
2.3.19	Western blotting.....	57
2.3.20	Serum harvest from whole blood.....	57
2.3.21	ELISA.....	58
2.3.22	<i>In vivo</i> tumor growth in nude Balb/c mice	58
2.3.23	Murine blood collection via eye bleed	59
2.3.24	Murine blood collection via heart venupuncture	59
2.3.25	Mouse urine collection	60
2.3.26	Immunohistochemical staining	60
2.4	Data Analysis.....	61
 CHAPTER 3: Expression and quantification of osteopontin and its alternatively spliced variants in cultured cell lines and liver tissue		
		62
3.1	Introduction	62
3.2	Results	64
3.2.1	mRNA expression of OPN and its variants in cultured cell lines.....	64
3.2.2	mRNA expression patterns of OPN and its variants in non-diseased, HCV-infected and HCC-tumor bearing liver tissue	65
3.2.3	Quantitation of OPN in different stages of HCV-related liver disease.....	66
3.2.4	Quantitation of OPN in HCC tumor tissue compared to cognate non-neoplastic liver	68
3.2.5	Quantitative assessment of OPN variant expression: real-time RT-PCR	68
3.2.5.1	Primer design and validation	69

3.2.5.2	Evaluation of primer efficiency	70
3.2.5.3	Ability of primers to accurately quantitate relative OPN levels from known input dilution series.....	71
3.2.5.4	Ability of primers to accurately quantitate relative OPN levels from mixed input samples	72
3.2.5.5	Analysis of primer cross-reactivity	73
3.2.6	Quantitative assessment of OPN variant expression: GeneScan [®] Genotyping PCR	74
3.3	Discussion	76
3.3.1	Expression of OPN and its variants in HCC-derived cell lines and HCV-infected and HCC tissues	76
3.3.2	Quantitation of OPN variants	79
3.3.3	Future directions	81
CHAPTER 4: OPN and its role in cellular proliferation of HCC cell lines <i>in vitro</i>		82
4.1	Introduction	82
4.2	Results	83
4.2.1	Generation of OPN variant expression vectors.....	83
4.2.2	Confirmation of OPN expression following transient transfection of OPN variant vectors.....	83
4.2.3	OPN ELISA for detection of secreted OPN	84
4.2.3.1	Optimisation of in-house OPN ELISA	84

4.2.3.2	Confirmation of OPN secretion following transient transfection of OPN variant vectors.....	85
4.2.4	Intracellular detection of OPN splice variants.....	86
4.2.5	Generation of OPN stable transfectant Huh-7 cell lines	88
4.2.6	Effect of OPN on HCC-derived cell line proliferation	89
4.2.6.1	Effect of intracellular OPN expression on hepatoma cell proliferation.....	90
4.2.6.2	Secreted OPN increases proliferation of naïve hepatoma cells.....	91
4.2.6.3	Blocking cell surface binding of OPN abrogates hepatoma cell proliferation.	92
4.2.7	Effect of OPN-CD44 interaction on hepatoma cell proliferation.....	93
4.2.7.1	CD44 expression in carcinoma cell lines	94
4.2.7.2	Effect of cellular CD44 status on OPN-induced increases in carcinoma cell proliferation.....	95
4.2.7.3	Effect of siRNA knockdown of CD44 on OPN-induced increases in cellular proliferation.....	96
4.2.7.4	Optimisation and validation of CD44 knockdown	96
4.2.7.5	Effect of siRNA knockdown of CD44 on OPN-induced increases in cellular proliferation.....	99
4.2.7.6	Effect of blocking CD44-OPN interactions on OPN-mediated increases in carcinoma cell proliferation	100
4.2.8	Effect of OPN on CD44 expression.....	101
4.3	Discussion	102

4.3.1	OPN increases proliferation of hepatoma cell lines in a paracrine manner through interaction with CD44.....	102
4.3.2	Future directions	105
CHAPTER 5: Effect of osteopontin expression on subcutaneous tumor growth <i>in vivo</i> in a nude Balb/C mouse model		
107		
5.1	Introduction	107
5.2	Results	108
5.2.1	Development of subcutaneous Huh-7 xenograft tumors in nude Balb/c mice	108
5.2.2	Effect of OPN on Huh-7 derived xenograft growth.....	111
5.2.3	Detection of OPN expression and secretion in tumor xenografts derived from OPN stable transfectant cell lines	114
5.2.4	Effect of tumor OPN secretion on growth of neighbouring Huh-7 derived xenografts.....	116
5.3	Discussion	117
5.3.1	OPN expression increases growth rate of Huh-7 derived tumor xenografts	117
5.3.2	Future directions	120
CHAPTER 6: Osteopontin expression in HCV-related liver disease: cellular expression and its potential as a serum biomarker		
124		
6.1	Introduction	124
6.2	Results	126
6.2.1	Expression of OPN in patients with HCV-related liver disease and HCC compared to non-diseased individuals.....	126

6.2.1.1	Sample collection and patient characteristics	126
6.2.1.2	Serum OPN expression in HCV-related liver disease, including HCC	127
6.2.1.3	Cellular OPN expression in HCV-related liver disease, including HCC	131
6.2.2	Expression of OPN in patients with HBV and alcohol related liver disease and HCC	133
6.3	Discussion	137
6.3.1	Serum and liver OPN levels are increased in HCV-related liver disease including HCC.....	137
6.3.2	Future directions	141
CHAPTER 7: Concluding Remarks.....		143
Appendix 1.....		147
Appendix 2.....		149
Bibliography		151

Abstract

Osteopontin (OPN) is a highly secreted multi-functional sialoprotein that is widely expressed in tissues, blood and urine. It is involved in a number of normal physiological functions, but is also significantly elevated in a number of cancers. While OPN is significantly expressed in hepatocellular carcinoma (HCC) little is known as to its role and if it is expressed in the pre-cancerous hepatitis C virus (HCV) infected liver.

In this thesis we show that OPN is expressed in the liver and in HCC as three variants, the full-length protein OPN-A and two splice variants OPN-B and OPN-C. Through production of stable Huh-7 cells expressing the OPN variants, we show for the first time that all variants increase proliferation of a range of cultured hepatoma cell lines in a paracrine manner through interactions with the cell surface OPN receptor CD44. Similarly, OPN-A (and to a lesser extent OPN-B and –C) accelerated Huh-7 derived tumor growth in a nude mouse model. We also show for the first time expression of all three OPN variants in the non-diseased liver as it was previously thought that splicing was a feature specific for tumor cells.

Clinically, OPN is known to be highly expressed in HCC, however, its expression in chronic hepatitis C is not well documented. In this thesis we show that OPN mRNA expression is elevated in the HCV-infected liver with a trend towards increased expression as liver disease progresses. Consistent with an increase in mRNA, serum OPN levels were also increased in the HCV-infected liver although we could find no correlation with degree of liver disease. However, our sample size was small and this section of the thesis needs repeating with a larger HCV-infected patient cohort. Furthermore, we show that elevated OPN expression is not specific to the HCV-infected liver as OPN is also elevated in the HBV-infected and alcoholic liver

suggesting that HCV does not drive OPN expression but is more likely as a result of the inflammatory process in the viral infected liver. Interestingly we also show that there is a shift of OPN expression from bile duct epithelial cells in the non-diseased liver to the hepatocyte in the HCV-infected liver which raises the question as to the role of OPN in hepatocyte transformation to facilitate the development of HCC. Our evaluation of serum OPN expression also suggests that OPN has potential as both a diagnostic and potentially prognostic biomarker for not only HCC (arising from HBV and HCV infections and alcohol abuse) but also the earlier stages of HCV-related liver disease.

This work for the first time characterises the expression of all OPN variants in the liver including HCC and may be useful for identifying targeted OPN-based therapeutic approaches for HCC and other cancers. Furthermore it also suggests that monitoring OPN in chronic hepatitis C may be useful in monitoring liver disease progression and early detection of HCC.

Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Renée Jade Phillips and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.



Renée Jade Phillips, B. Biotech (Hons)

April, 2010

Presentations and publications related to this thesis

Publications:

Renée J. Phillips, Karla J. Helbig, Kylie van der Hoek, Devanshi Seth and Michael R. Beard (2010). Osteopontin increases hepatocellular carcinoma cell growth through interactions with CD44. *Submitted (Hepatology)*.

Conference Presentations (presenter in bold type):

Renée J. Phillips, Karla J. Helbig, Andrew R. Ruszkiewicz and **Michael R. Beard**. Osteopontin is significantly expressed in advanced HCV-related liver disease and can accelerate Huh-7 growth *in vitro* and in a nude mouse model. *4th Hong Kong-Shanghai International Liver Congress*, Hong Kong, 2008.

Renée J. Phillips, Karla J. Helbig, Andrew R. Ruszkiewicz and Michael R. Beard. Osteopontin is significantly expressed in advanced HCV-related liver disease and can accelerate Huh-7 growth *in vitro* and in a nude mouse model. *42nd Annual Meeting of the European Association for the Study of the Liver*. Barcelona, Spain, 2007 (poster presentation).

Renée J. Phillips, Karla J. Helbig, Andrew R. Ruszkiewicz and Michael R. Beard. Osteopontin is expressed in advanced HCV-related liver disease and can accelerate hepatocyte growth *in vitro*. *13th International Meeting on Hepatitis C Virus and Related Viruses*. Cairns, Australia, 2006.

Renée J. Phillips (McKay), Karla J. Helbig and Michael R. Beard. The role of osteopontin in hepatitis C virus-related liver disease and hepatocellular carcinoma. *Australian Society for Medical Research (ASMR) Medical Research Week Scientific Meeting (SA)*. Adelaide, SA, Australia, 2005.

Renée J. Phillips (McKay), Karla J. Helbig and Michael R. Beard. The role of osteopontin in hepatitis C virus-related liver disease and hepatocellular carcinoma. *2nd Australian Centre for Hepatitis Virology and HIV Virology National Scientific Meeting*. Terrigal, NSW, Australia, 2005.

Acknowledgements

Firstly I would like to thank my principal supervisor Assoc. Prof. Michael Beard and co-supervisor Dr. Allison Jilbert for providing unwavering support, guidance, advice and encouragement over the course of both my Honours year and my PhD.

Sincere thanks to all current and former members of the Hepatitis C Research Group who have assisted me both professionally and personally over the last few years. Special thanks go to Dr. Karla Helbig who initiated the work on osteopontin that formed the starting point of my project and for her constant advice and suggestions, Mrs. Ljiljana Semendric and Mrs. Gorjana Radisic who taught me most of what I know technically, and Dr. Kylie van der Hoek for her invaluable help with immunohistochemistry and histology. Thank you also to Nick, Erin, Evelyn, Eddie, Susan and all our past honours students for your friendship, technical expertise, proof reading and snack food.

To everyone from other laboratories who helped me with reagents, equipment and advice, I could not have done it without you. Thank you to my fellow PhD students who have helped keep my sanity in check, and who understand so well the life of a graduate student. I would also like to acknowledge the following individuals and organisations who donated patient specimens for this study: Dr. Hugh Harley (Royal Adelaide Hospital), Dr. Ed Gane (Auckland Hospital), Dr. Tin Nguyen (Royal Prince Alfred Hospital), the Institute of Medical and Veterinary Sciences and the Australian Red Cross Blood Service.

Finally I would like to thank my husband Brad for encouraging me to continue with my studies, and my family and friends who have been very patient in allowing me to be a student for the past 10 years.

List of Figures and Tables

Figure Number		On or follows page:
Chapter 1		
Figure 1.1	Geographical distribution of HCV genotypes	1
Figure 1.2	Worldwide prevalence of HCV	2
Figure 1.3	Australian HCV notifications	2
Figure 1.4	Outcomes of HCV infection	3
Figure 1.5	Course of acute HCV infection	4
Figure 1.6	Course of chronic HCV infection	4
Figure 1.7	Natural history of chronic HCV infection	5
Figure 1.8	Pathogenesis of chronic HCV infection	7
Figure 1.9	HCV genome	10
Figure 1.10	HCV life cycle	11
Figure 1.11	Yearly worldwide HCC incidence	13
Figure 1.12	Proposed sequence of hepatocarcinogenesis	16
Figure 1.13	OPN gene structure and binding domains	23
Figure 1.14	Proposed OPN secondary structure	24
Figure 1.15	CD44 gene structure	26
Figure 1.16	OPN splice variants	29
Figure 1.17	OPN-induced tumor growth and metastasis pathways	32
Table 1.1	Previous OPN biomarker studies	34
Table 1.2	Diagnostic accuracy of OPN, AFP and PIVKA II in HCC	38
Figure 1.18	Diagnostic effectiveness of OPN, AFP and PIVKA II in HCC	38

Chapter 2

Figure 2.1	pRc/CMV vector map	41
Table 2.1	Primers used in this study	41
Table 2.2	Cell culture requirements	42
Figure 2.2	G418 calculations for selection of stable transfectants	43
Table 2.3	Antibodies used in this study	55

Chapter 3

Figure 3.1	OPN staining by IHC in human and murine HCC	62
Figure 3.2	OPN mRNA expression in cultured cell lines	64
Figure 3.3	Primer locations for concurrent amplification of OPN variants	64
Figure 3.4	OPN variant mRNA expression in cultured cell lines	64
Figure 3.5	OPN mRNA expression in liver and tumor tissue	65
Figure 3.6	OPN variant mRNA expression in human liver and tumor tissue	65
Figure 3.7	OPN variant mRNA expression in murine liver and tumor tissue	66
Table 3.1	Grouping of HCV mRNA samples based on fibrosis grade	67
Figure 3.8	OPN levels in HCV-infected livers of varying fibrosis grades	67
Figure 3.9	OPN levels in HCC tumor tissue and cognate cirrhotic tissue	68
Figure 3.10	Specificity of OPN variant real-time RT-PCR primers	70
Figure 3.11	Locations of OPN variant real-time RT-PCR primers	70
Figure 3.12	Specificity of OPN variant real-time RT-PCR primers (second set)	70
Figure 3.13	OPN variant primer pair efficiency	70
Figure 3.14	Alternative OPN-A primer pair amplification	71
Figure 3.15	Alternative OPN-A primer pair efficiency	71
Figure 3.16	Relative OPN variant quantitation	72

Table 3.2	Relative OPN variant quantitation	72
Table 3.3	OPN variant quantitation: single versus mixed template	73
Figure 3.17	Cross-reactivity of OPN-A primer pair	73
Figure 3.18	Cross-reactivity of OPN-B primer pair	73
Figure 3.19	Cross-reactivity of OPN-C primer pair	74
Figure 3.20	Locations of GeneScan [®] primers	74
Figure 3.21	Optimisation of GeneScan [®] amplification method	75
Figure 3.22	Validation of GeneScan [®] amplification method	75
Figure 3.23	GeneScan [®] results	75
Table 3.4	GeneScan [®] results	76
Chapter 4		
Figure 4.1	Confirmation of successful cloning of OPN variants	83
Figure 4.2	OPN variant over-expression following transient transfection	84
Figure 4.3	Optimisation of in-house OPN ELISA	85
Table 4.1	Secretion of OPN variants from transfected Huh-7 cells	86
Figure 4.4	Visualisation of OPN variants in transfected Huh-7 cells	87
Figure 4.5	OPN variant secretion from stable transfectant Huh-7 cells	88
Figure 4.6	OPN variant mRNA over-expression in stable transfectants	89
Figure 4.7	OPN expression and secretion from stable transfectants (WB)	89
Figure 4.8	OPN variant expression increases Huh-7 proliferation	91
Figure 4.9	OPN variant secretion increases Huh-7 proliferation	91
Figure 4.10	OPN variant secretion increases HepG2 proliferation	92
Figure 4.11	OPN antibody abrogates OPN-mediated Huh-7 proliferation	93
Figure 4.12	CD44 mRNA and protein expression in cultured cell lines	95

Figure 4.13	OPN variant secretion increases HeLa but not Hep3B proliferation	95
Figure 4.14	RNAi interference pathway	96
Figure 4.15	Huh-7 and HeLa siRNA transfection efficiency	97
Figure 4.16	Location of CD44 siRNA oligonucleotides	97
Figure 4.17	CD44 mRNA knockdown in Huh-7 and HeLa by siRNA	98
Figure 4.18	CD44 protein knockdown in HeLa by siRNA	99
Figure 4.19	Prolonged CD44 mRNA knockdown in Huh-7 and HeLa	99
Figure 4.20	Prolonged CD44 protein knockdown in HeLa	99
Figure 4.21	CD44 knockdown abrogates OPN-mediated Huh-7 and HeLa proliferation	100
Figure 4.22	CD44 antibody abrogates OPN-mediated Huh-7 and HeLa proliferation	101
Figure 4.23	OPN expression does not affect CD44 expression in Huh-7 cells	102
 Chapter 5		
Table 5.1	Previous Huh-7 xenograft studies	109
Figure 5.1	Subcutaneous injection of Huh-7 into nude mice	109
Table 5.2	Day of Huh-7 tumor appearance	110
Figure 5.2	Representative Huh-7 tumor xenograft	110
Figure 5.3	Confirmation of human origin of Huh-7 xenograft	111
Table 5.3	Tumor take rate of OPN transfectant Huh-7 xenografts	112
Figure 5.4	Day of OPN transfectant tumor appearance	112
Figure 5.5	OPN transfectant xenograft growth	112
Figure 5.6	Visualisation of OPN transfectant tumors	113
Figure 5.7	OPN transfectant tumor histology	113

Figure 5.8	OPN variant mRNA expression in OPN transfectant tumors	114
Figure 5.9	OPN protein expression in OPN transfectant tumors (IHC)	115
Figure 5.10	Tumor groups for OPN secretion test	116
Table 5.4	Tumor take rate of OPN-A and Huh-7 tumors	116
Figure 5.11	Day of tumor appearance	117
Figure 5.12	OPN transfectant xenograft growth	117
Chapter 6		
Table 6.1	Previous OPN biomarker studies	124
Table 6.2	Patient characteristics: HCV-related liver disease and HCC	127
Figure 6.1	Serum OPN levels: HCV-related liver disease and HCC	127
Table 6.3	Serum OPN comparisons: HCV-related liver disease and HCC	128
Table 6.4	Grouping of HCV-infected serum samples by fibrosis grade	129
Figure 6.2	Serum OPN levels: HCV-related liver disease by fibrosis grade	129
Table 6.5	Patient characteristics: HBV, ethanol and HCV-related HCC	130
Figure 6.3	Serum OPN levels: HCV-related liver disease by activity score	130
Table 6.6	Serum OPN comparisons: HBV, ethanol and HCV-related HCC	131
Figure 6.4	OPN protein expression in HCV-related liver disease	132
Figure 6.5	OPN protein expression in HCV-related liver disease	132
Table 6.7	Patient characteristics: HBV, ethanol and HCV-related and HCC	134
Figure 6.6	Serum OPN levels: HBV, ethanol and HCV-related HCC	134
Table 6.8	Serum OPN comparisons: HBV, ethanol and HCV-related and HCC	135
Table 6.9	Patient characteristics: HBV-related liver disease and HCC	136
Figure 6.7	Serum OPN levels: HBV-related liver disease and HCC	136
Table 6.10	Serum OPN comparisons: HBV-related liver disease and HCC	137

Abbreviations

6-FAM	6-carboxyfluorescein
A	adenosine
AFB ₁	aflatoxin B1
AFLP	amplified fragment length polymorphism
AFP	alpha-fetoprotein
AFP-L3	lens culinaris agglutinin-reactive AFP
AFU	α -1-fucosidase
aka	also known as
ALT	alanine transaminase
ANOVA	analysis of variance
AP-1	activator protein 1
AP2	activating protein 2
AUC	area under the curve
bp	base pairs
BSA	bovine serum albumin
C	cytosine
°C	degrees centigrade
CA 125	cancer antigen 125
CDC	Centres for Disease Control
cDNA	complimentary DNA
CHC	chronic hepatitis C
cm	centimeter(s)
CO ₂	carbon dioxide

DAB	3,3'-diaminobenzidine
DAPI	4',6-diamidino-2-phenylindole
dATP	deoxyadenosine-5'-triphosphate
DCP	des- γ -carboxy prothrombin
dCTP	deoxycytosine-5'-triphosphate
DFS	disease-free survival
dGTP	deoxyguanosine-5'-triphosphate
dH ₂ O	deionised water
DMEM	Dulbecco's Modified Eagle Medium with HEPES
DMSO	dimethyl sulphoxide
DNA	deoxyribonucleic acid
dNTP	deoxyribonucleotide triphosphate
dTTP	deoxythymidine-5'-triphosphate
ECM	extracellular matrix
EDTA	ethylene diamine tetra acetic acid
EGF	epidermal growth factor
EGFR	EGF receptor
ELISA	enzyme linked immunosorbent assay
ER	endoplasmic reticulum
ERK	extracellular signal-regulated kinase
Eta-1	early T-cell activation factor
EtOH	ethanol
F	fibrosis
FCS	foetal calf serum
FDA	Food and Drug Administration

FITC	fluorescein isothiocyanate
g/L	grams per litre
G	guanosine
GAPDH	glyceraldehyde-3-phosphate dehydrogenase
GEP	granulin-epithelin precursor
GFP	green fluorescent protein
GP73	golgi protein 73
GPC3	glypican 3
H&E	haematoxylin and eosin
HAI	histological activity index
HAV	hepatitis A virus
HBV	hepatitis B virus
HBx	hepatitis B virus X protein
HCC	hepatocellular carcinoma
HCV	hepatitis C virus
HEPES	N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid
HGF	hepatocyte growth factor
HIV	Human Immunodeficiency Virus
HRP	horseradish peroxidase
HSC	hepatic stellate cell
IDU	injecting drug use(rs)
IF	immunofluorescence
IFN- γ	interferon gamma
IFN- λ	interferon lambda
IgG	immunoglobulin G

IHC	immunohistochemistry
IL-x	interleukin x
IMVS	Institute of Medical and Veterinary Sciences
iNOS	inducible nitric oxide synthase
IRES	internal ribosome entry site
IRF-1	interferon regulatory factor-1
IU	international units
kDa	kilodalton
L	litre
LB	Luria Bertani broth
LDL	low density lipoprotein
μg	microgram(s)
μl	microlitre(s)
μm	micrometer(s)
μM	micromolar
μmol	micromole(s)
MAPK	mitogen-activated protein kinase
mAU	milli-absorbance units
mg	milligram(s)
MIA	melanoma inhibitory activity
ml	millilitre(s)
mm	millimeter(s)
mM	millimolar
MCS	multiple cloning site
mRNA	messenger RNA

MW	molecular weight
MWM	molecular weight marker
n/a	not applicable
n/avail	not available
NAFLD	non-alcoholic fatty liver disease
NANBH	non-A non-B hepatitis
NASH	non-alcoholic steatosis
NCI	National Cancer Institute
n.d.	not determined/not detected
ng	nanogram(s)
NIH	National Institute of Health
NHL	normal human liver
NKT	natural killer T
nm	nanometer(s)
nM	nanomolar
NML	normal mouse liver
NTC	no template control
OPN	osteopontin
ORF	open reading frame
OS	overall survival
PAGE	polyacrylamide gel electrophoresis
PBS	phosphate buffered saline
PBS-T	PBS-Tween 20
PCR	polymerase chain reaction
PDGF	platelet derived growth factor

peg-IFN- α	pegylated interferon alpha
PEI	percutaneous ethanol injection
pg	picogram(s)
PIVKA-II	protein induced by vitamin K absence
pmol	picomole(s)
pro-MMP-2	pro-matrix metalloprotease-2
PSA	prostate specific antigen
RISC	RNA-induced silencing complex
RNA	ribonucleic acid
RNAi	RNA interference
ROC	receiver operating characteristics
RPLPO	ribosomal protein, large, P0
rpm	revolutions per minute
RT-PCR	reverse transcriptase PCR
SCCA	squamous cell carcinoma antigen
SDS	sodium dodecyl sulfate
SIBLING	small integrin-binding ligand N-linked glycoprotein
siRNA	short interfering RNA
SNP	single nucleotide polymorphism
SPP1	secreted phosphoprotein 1
STAT-C	specifically targeted antiviral therapy for hepatitis C
SVR	sustained virological response
T	thymidine
TAE	Tris/acetic acid/EDTA
TEMED	N,N,N',N'-tetramethylethylenediamine

TNF- α	tumor necrosis factor alpha
Tris	3,3,5,5-tetramethylbenzidine
U/L	units per litre
uPA	urokinase plasminogen activator
US	United States of America
UTR	untranslated region
UV	ultraviolet
VDRE	vitamin D responsive element
VEGF	vascular endothelial growth factor
v/v	volume per volume
WB	western blotting
WHO	World Health Organisation
w/v	weight per volume

Materials Providers

Ambion	Austin, Texas, USA
Amersham Pharmacia Biotech (GE Healthcare)	Piscataway, New Jersey, USA
AppliChem	Darmstadt, Germany
Applied Biosystems	Foster City, California, USA
BD Biosciences	Franklin Lakes, New Jersey, USA
BDH (Merck)	Poole, UK
Becton Dickinson Labware	Franklin Lakes, New Jersey, USA
BioRad Laboratories	Hercules, California, USA
Biotium Inc.	Hayward, California, USA
Canon	Tokyo, Japan
Cell Signaling	Danvers, Massachusetts, USA
Chemicon (Millipore)	Billerica, Massachusetts, USA
Corning Costar [®]	Lowell, Massachusetts, USA
CSL	Parkville, VIC, Australia
Dako	Glostrup, Denmark
Diploma (Fonterra Brands)	Mt. Waverley, VIC, Australia
Dynatech Laboratories	Chantilly, Virginia, USA
GeneWorks	Hindmarsh, SA, Australia
Gibco BRL (Invitrogen)	Carlsbad, California, USA
Greiner Bio-one	Frickenhausen, Germany
Invitrogen	Carlsbad, California, USA
Kodak	Rochester, New York, USA
Livingstone	Rosebery, NSW, Australia

Menzel-Glaser®	Braunschweig, Germany
Mo Bio Laboratories	Carlsbad, California, USA
Molecular Probes	Eugene, Oregon, USA
Nalgene	Rochester, New York, USA
NeoMarkers (LabVision)	Fremont, California, USA
New England Biolabs	Ipswich, Massachusetts, USA
Nunc (ThermoFisher Scientific)	Roskilde, Denmark
Olympus	Tokyo, Japan
Pharmacia (Pfizer)	New York, New York, USA
Promega	Madison, Wisconsin, USA
Qiagen	Hilden, Germany
Roche	Basel, Switzerland
R&D Systems	Minneapolis, Minnesota, USA
Rockland	Gilbertsville, Pennsylvania, USA
Santa Cruz Biotechnology	Santa Cruz, California, USA
Sigma	St. Louis, Missouri, USA
SPSS Inc.	Chicago, Illinois, USA
Techno-Plas	St. Marys, SA, Australia
Trace Biosciences	Castle Hill, NSW, Australia